According to RaiaDrogasil's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 26.51. At the end of 2022 the company had a P/E ratio of 38.4.
Year | P/E ratio | Change |
---|---|---|
2022 | 38.4 | -28.06% |
2021 | 53.3 | -14.35% |
2020 | 62.3 | 30.66% |
2019 | 47.6 | 28.14% |
2018 | 37.2 | -37.25% |
2017 | 59.3 | 31.59% |
2016 | 45.0 | 31.12% |
2015 | 34.3 | -8.89% |
2014 | 37.7 | -22.05% |
2013 | 48.4 | -34.7% |
2012 | 74.0 | 106.23% |
2011 | 35.9 | 30.73% |
2010 | 27.5 | 26.89% |
2009 | 21.6 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.